Apatinib potentiates irradiation effect via suppressing PI3K/AKT signaling pathway in hepatocellular carcinoma

Apatinib potentiates irradiation effect via suppressing PI3K/AKT signaling pathway in hepatocellular carcinoma

Abstract Background Limited effective intervention for advanced hepatocellular carcinoma (HCC) is available. This study aimed to investigate the potential clinical utility of apatinib, a highly selective inhibitor of the vascular endothelial growth factor receptor-2 (VEGFR2) tyrosine kinase, as a ra...

Full description

Bibliographic Details
Main Authors:	Junbin Liao, Huilin Jin, Shaoqiang Li, Lixia Xu, Zhenwei Peng, Guangyan Wei, Jianting Long, Yu Guo, Ming Kuang, Qi Zhou, Sui Peng
Format:	Article
Language:	English
Published:	BMC 2019-11-01
Series:	Journal of Experimental & Clinical Cancer Research
Subjects:	Hepatocellular carcinoma Apatinib Irradiation Radiosensitization PI3K/AKT pathway
Online Access:	http://link.springer.com/article/10.1186/s13046-019-1419-1

Similar Items

A novel role for apatinib in enhancing radiosensitivity in non-small cell lung cancer cells by suppressing the AKT and ERK pathways
by: Lin Li, et al.
Published: (2021-10-01)

Overexpression of IGFBP5 Enhances Radiosensitivity Through PI3K-AKT Pathway in Prostate Cancer
by: Chen X, et al.
Published: (2020-07-01)

Combination of Cordycepin and Apatinib Synergistically Inhibits NSCLC Cells by Down-Regulating VEGF/PI3K/Akt Signaling Pathway
by: Xiaozhong Liao, et al.
Published: (2020-09-01)

Apatinib Inhibits Angiogenesis Via Suppressing Akt/GSK3β/ANG Signaling Pathway in Anaplastic Thyroid Cancer
by: Zhijian Jin, et al.
Published: (2017-12-01)

Apatinib affect VEGF-mediated cell proliferation, migration, invasion via blocking VEGFR2/RAF/MEK/ERK and PI3K/AKT pathways in cholangiocarcinoma cell
by: Manping Huang, et al.
Published: (2018-11-01)

Apatinib Inhibits Cell Proliferation and Induces Autophagy in Human Papillary Thyroid Carcinoma via the PI3K/Akt/mTOR Signaling Pathway
by: Xiangrui Meng, et al.
Published: (2020-03-01)

Targeting PI3K/AKT/mTOR Signaling Pathway as a Radiosensitization in Head and Neck Squamous Cell Carcinomas
by: Yu-Chieh Su, et al.
Published: (2022-12-01)

Apatinib suppresses tumor progression and enhances cisplatin sensitivity in esophageal cancer via the Akt/β-catenin pathway
by: Bin Wei, et al.
Published: (2020-05-01)

Upregulation of miR-214 Induced Radioresistance of Osteosarcoma by Targeting PHLDA2 via PI3K/Akt Signaling
by: Yi Li, et al.
Published: (2019-04-01)

Effective Treatment of Low-Grade Myofibroblastic Sarcoma with Apatinib: A Case Report and Literature Review
by: Lin Y, et al.
Published: (2022-06-01)

DNA polymerase ζ suppresses the radiosensitivity of glioma cells by regulating the PI3K/AKT/mTOR pathway
by: Jiqiang Ding, et al.
Published: (2023-12-01)

The efficacy and safety of Apatinib combined with TACE in the treatment of hepatocellular carcinoma: a meta-analysis
by: Anan Gong, et al.
Published: (2022-03-01)

Experimental study of the vascular normalization window for tumors treated with apatinib and the efficacy of sequential chemotherapy with apatinib in lung cancer‐bearing mice and patients
by: Mingtao Liu, et al.
Published: (2020-04-01)

Downregulation of fibulin‐4 inhibits autophagy and promotes the sensitivity of esophageal squamous cell carcinoma cells to apatinib by activating the Akt‐mTOR signaling pathway
by: Xiangyu Chen, et al.
Published: (2022-09-01)

Regulation of ferroptosis by PI3K/Akt signaling pathway: a promising therapeutic axis in cancer
by: Hua Su, et al.
Published: (2024-03-01)

Anorexia, Hypertension, Pneumothorax, and Hypothyroidism: Potential Signs of Improved Clinical Outcome Following Apatinib in Advanced Osteosarcoma
by: Xie L, et al.
Published: (2020-01-01)

The HIV protease and PI3K/Akt inhibitor nelfinavir does not improve the curative effect of fractionated irradiation in PC-3 prostate cancer in vitro and in vivo
by: Steffi Liebscher, et al.
Published: (2017-02-01)

An exploratory clinical trial of apatinib combined with intensity‐modulated radiation therapy for patients with unresectable hepatocellular carcinoma
by: Hu Qiu, et al.
Published: (2023-01-01)

The apatinib and pemetrexed combination has antitumor and antiangiogenic effects against NSCLC
by: Zhou Ling, et al.
Published: (2023-03-01)

Apatinib treatment for KIT- and KDR-amplified angiosarcoma: a case report
by: Lishu Yang, et al.
Published: (2018-05-01)

RETRACTED: A novel therapeutic strategy of combined camrelizumab and apatinib for the treatment of advanced hepatocellular carcinoma
by: Qing Yang, et al.
Published: (2023-03-01)

Clinical observation of apatinib in the treatment of metastatic colorectal cancer
by: CHEN Zhu, LIU Yan, GAO Li-hua, CHEN Bu-you, TANG Ai-hua, LIU Jun
Published: (2021-12-01)

Activity and safety of apatinib monotherapy or apatinib combined with chemotherapy for patients with metastatic or unresectable osteosarcoma over the age of 40 years: A retrospective analysis
by: Taojun Gong, et al.
Published: (2022-11-01)

Effect of nicastrin on hepatocellular carcinoma proliferation and apoptosis through PI3K/AKT signalling pathway modulation
by: Xicheng Wang, et al.
Published: (2020-03-01)

Efficacy Of Apatinib In Transcatheter Arterial Chemoembolization (TACE) Refractory Intermediate And Advanced-Stage Hepatocellular carcinoma：A Propensity Score Matching Analysis
by: Qiu Z, et al.
Published: (2019-11-01)

Efficacy and safety of apatinib in the treatment of osteosarcoma: a single-arm meta-analysis among Chinese patients
by: Hui Yao, et al.
Published: (2021-04-01)

Drug-related adverse events potentially predict the efficacy of apatinib on advanced hepatocellular carcinoma
by: Xiaoying Gu, et al.
Published: (2022-10-01)

Effect of apatinib on the pharmacokinetics of tramadol and O-desmethyltramadol in rats
by: Su-su Bao, et al.
Published: (2023-09-01)

Research Progress of Combination Therapy of Apatinib on Tumor
by: WU Shan, et al.
Published: (2019-03-01)

Progress of Apatinib in Treatment of Non-small Cell Lung Cancer
by: LIANG Lijun, et al.
Published: (2018-11-01)

The effect of apatinib combined with chemotherapy or targeted therapy on non‐small cell lung cancer in vitro and vivo
by: Mingtao Liu, et al.
Published: (2019-10-01)

Evaluation of models to predict prognosis in patients with advanced hepatocellular carcinoma treated with TACE combined with apatinib
by: Fang Sun, et al.
Published: (2024-04-01)

Phase 1 trial of apatinib combined with intensity-modulated radiotherapy in unresectable hepatocellular carcinoma
by: Hongzhi Wang, et al.
Published: (2022-07-01)

Targeting the PI3K/Akt/mTOR Pathway in Hepatocellular Carcinoma
by: Eun Jin Sun, et al.
Published: (2021-11-01)

Apatinib combined with SOX regimen for conversion therapy in advanced gastric cancer patients: a retrospective cohort study
by: Ya-Ya Deng, et al.
Published: (2023-04-01)

Apatinib for patients with advanced or recurrent cervical cancer: study protocol for an open-label randomized controlled trial
by: Jian-Guo Zhou, et al.
Published: (2018-09-01)

Apatinib as Salvage Therapy for Heavily Pretreated SCLC
by: Fangfang LI, et al.
Published: (2018-07-01)

Application effect of apatinib in patients with failure of standard treatment for advanced malignant tumours
by: Guohui Liu, et al.
Published: (2019-10-01)

Efficacy of Drug-Eluting Beads Transarterial Chemoembolization Plus Apatinib Compared with Conventional Transarterial Chemoembolization Plus Apatinib in the Treatment of Unresectable Hepatocellular Carcinoma
by: Zhang W, et al.
Published: (2021-07-01)

Getting the Akt Together: Guiding Intracellular Akt Activity by PI3K
by: Ivan Yudushkin
Published: (2019-02-01)